Skip to main contentAI and Advanced
/
ANTHEM · NSEBSE SENSEX77,537.72+0.82%BSE |
NIFTY 5024,231.85+0.64%NSE |
NIFTY BANK57,495.9+0.45%NSE |
NIFTY IT30,673.05+0.79%NSE |
NIFTY AUTO29,301.75+0.40%NSE |
NIFTY FMCG47,863.25+0.82%NSE |
NIFTY PHARMA26,416+0.39%NSE |
NIFTY 50023,512.95+0.54%NSE |
AN
NSE · Equity shares · Biotechnology & Drugs-5.05 · -0.57%
Anthem BioSciences ANTHEM
NSE:INR 874.15
BSE:INR 826.3
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ANTHEM
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 879.2
Day rangeINR 871.85 — INR 890
52-week rangeINR 579.15 — INR 904
Volume2.86 L
Market cap46,624.99
P/E75.18
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,124.33
Net Income (INR Cr)591.79
Rev Growth (5 Year %)14
EPS Growth (5 Year %)16.64
P/E Ratio75.18
EPS10.74
Research path: Interpret Anthem BioSciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ANTHEMAnthem BioSciences1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,429.29 | 2,807.58 | 2,398.11 |
| Accumulated Depreciation Total | -696.38 | -573.69 | -494.03 |
| Cash Equivalents | 272.91 | 171.45 | 183.86 |
| Other Liabilities Total | 32.44 | 21.6 | 18.87 |
| Accrued Expenses | 38.19 | 19.66 | 27.45 |
| Long Term Debt | 27.73 | 47.03 | 111.66 |
| Common Stock Total | 112.34 | 111.82 | 111.82 |
| Other Equity Total | -4.52 | -2.95 | -2.55 |
| Other Current Assets Total | 137.84 | 187.33 | 120.04 |
| Prepaid Expenses | 4.81 | 0.61 | 3.41 |
| Total Assets | 3,429.29 | 2,807.58 | 2,398.11 |
| Current Portof LT Debt/Capital Leases | 25.31 | 63.43 | 122.55 |
| Additional Paid-In Capital | 151.22 | 125.18 | 125.18 |
| Cash | 1.97 | 0.84 | 0.5 |
| Total Equity | 3,042.52 | 2,409.86 | 1,924.66 |
| Long Term Investments | 508.03 | 271.97 | 18.28 |
| Retained Earnings(Accumulated Deficit) | 2,783.47 | 2,175.81 | 1,690.21 |
| Total Common Shares Outstanding | 56.17 | 56.16 | 56.16 |
| Property/Plant/Equipment Total-Gross | 1,743.52 | 1,571.8 | 1,314.99 |
| Tangible Book Valueper Share Common Eq | 54.16 | 42.84 | 34.16 |
| Total Liabilities | 386.77 | 397.72 | 473.46 |
| Total Debt | 53.92 | 113.32 | 238.52 |
| Short Term Investments | 665.59 | 312.29 | 459.07 |
| Cashand Short Term Investments | 940.47 | 484.58 | 643.43 |
| Total Receivables Net | 593.5 | 459.91 | 490.64 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Accounts Receivable-Trade Net | 590.64 | 450.43 | 490.63 |
| Property/Plant/Equipment Total-Net | 1,047.14 | 998.11 | 820.97 |
| Total Current Liabilities | 325.71 | 326.23 | 338.63 |
| Total Inventory | 126.52 | 355.75 | 224.04 |
| Accounts Payable | 75.22 | 110.09 | 100.74 |
| Other Currentliabilities Total | 187 | 133.05 | 87.88 |
| Total Long Term Debt | 28.62 | 49.88 | 115.96 |
| Intangibles Net | 0.44 | 3.87 | 6.24 |
| Other Long Term Assets Total | 47.27 | 35.44 | 59.24 |
| Note Receivable-Long Term | 23.27 | 10.02 | 11.83 |
| Total Current Assets | 1,803.15 | 1,488.17 | 1,481.55 |
| Capital Lease Obligations | 0.88 | 2.86 | 4.31 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio5.41
Price to Sale Ratio21.95
Growth
Debt 5Yr CAGR %-12.03
Margins
Operating Margin 12m31.51
Operating Margin 5y Avg34.07
Net Profit Margin 12m28.76
Net Profit Margin 5y28.67
Yield
Dividend Yield %0.24
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk27.27
Analyst consensus
ConsensusBuy
Consensus score2.33
Analyst opinions3
Strong Sell count0
Sell count0
Hold count1
Buy count2
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 71.42%
- FII
- 2.57%
- MF
- 11.15%
- Other
- 14.86%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
With EPS Growth And More, Anthem Biosciences (NSE:ANTHEM) Makes An Interesting Case - simplywall.stMarket news · 21 Jul 2026, 6:03 am
With EPS Growth And More, Anthem Biosciences (NSE:ANTHEM) Makes An Interesting Case simplywall.st
Anthem Biosciences - Jio Financial Services among 6 stocks showing bullish RSI upswing - The Economic TimesMarket news · 20 Jul 2026, 8:47 am
Anthem Biosciences - Jio Financial Services among 6 stocks showing bullish RSI upswing The Economic Times
Anthem Biosciences to host Q1 FY27 earnings call on July 22 - scanx.tradeMarket news · 15 Jul 2026, 9:42 pm
Anthem Biosciences to host Q1 FY27 earnings call on July 22 scanx.trade
Anthem Biosciences confirms no encumbrance on promoter shares in FY26 - scanx.tradeMarket news · 9 Jul 2026, 5:36 am
Anthem Biosciences confirms no encumbrance on promoter shares in FY26 scanx.trade
Anthem Biosciences IPO opens for subscription: Check price band, lot size and key points to know - UpstoxMarket news · 3 Jul 2026, 12:30 pm
Anthem Biosciences IPO opens for subscription: Check price band, lot size and key points to know Upstox
Anthem Biosciences IPO: Issue booked nearly 64x on day 3, QIBs take lead; here's how to check allotment - UpstoxMarket news · 3 Jul 2026, 12:30 pm
Anthem Biosciences IPO: Issue booked nearly 64x on day 3, QIBs take lead; here's how to check allotment Upstox
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.2.0000 per share(100%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
ShareKeyX Community
Discussion and sentiment for Anthem BioSciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Anthem Biosciences Limited is an India-based contract research, development and manufacturing organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. The Company’s segments include CRDMO and Speciality Ingredients. The Company helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and others. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its CRDMO Services include Large Molecules, Small Molecules, HPAPI, Peptides, Lipids, ADCs and Oligonucleotides.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ANTHEM
- BSE Code
- 544449
Questions
Stock FAQ
What is the symbol and ISIN of Anthem BioSciences?
Anthem BioSciences has the symbol ANTHEM and ISIN - INE0CZ201020.
What is the current price of Anthem BioSciences?
Anthem BioSciences is currently trading at INR 874.15.
What are the year high and year low of Anthem BioSciences?
Anthem BioSciences has a year high of INR 904.00 and a year low of INR 579.15.
What is the market capitalization of Anthem BioSciences?
Anthem BioSciences has a market capitalization of INR 46,624.99 crore.
What is the P/E ratio of Anthem BioSciences?
Anthem BioSciences has a P/E ratio of 75.18.
What is the dividend yield of Anthem BioSciences?
Anthem BioSciences has a dividend yield of 0.24%.
How is the financial performance of Anthem BioSciences based on revenue, net income, and EPS?
Anthem BioSciences has revenue of INR 2,124.33 crore, net income of INR 591.79 crore, and EPS of INR 10.48.
What is the book value of Anthem BioSciences?
Anthem BioSciences has a book value of NA.
What is the debt-to-equity ratio of Anthem BioSciences?
Anthem BioSciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Anthem BioSciences?
Anthem BioSciences has a price-to-book ratio of NA and a price-to-sales ratio of 21.95.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.